Target validation is one of rate-limiting steps in the modern drug discovery. The authors developed a strategy of combining adenovirus-mediated gene transfer for efficient target functionality validation, both in vivo and in vitro, with baculovirus expression to produce sufficient quantities of protein for high-throughput screening (HTS). The incorporation of green fluorescent protein (GFP) in the adenovirus vectors accelerates recombinant adenovirus plaque purification, whereas the use of epitope and affinity tags facilitates the identification and purification of recombinant protein. In this generalized scheme, the flexible modular design of viral vectors facilitates the transition between target validation and HTS. In the example presented, functional target validation in vivo was achieved by overexpressing the target gene in cell-based models and in the mouse cortex following adenovirus-mediated gene delivery. In this context, target overexpression resulted in the accumulation of a disease-related biomarker both in vitro and in vivo. A baculovirus-based expressional system was then generated to produce enough target protein for HTS. Thus, the use of these viral expression systems represents a generalized method for rapid target functionality validation and HTS assay development, which could be applied to numerous target candidates being elucidated in gene discovery programs. (Journal of Biomolecular Screening 2003:65-71) 
INTRODUCTION T HE DEVELOPMENT OF GENOMICS AND BIOINFORMATICS has
led to the continual identification of a large volume of potential drug discovery targets. This onslaught of information has made the development of rapid and efficient target validation methods necessary. In addition, the pharmaceutical industry requires rapid high-throughput screening (HTS) of these targets, necessitating robust and rapid production of reagents and assays. Traditional methods of target validation frequently depend on fairly timeconsuming and expensive generation of transgenic animals to achieve altered activity of target genes. 1 Adenoviral expression systems, on the other hand, are easy to produce and allow efficient delivery of target genes both in vivo and in vitro. 2, 3 We describe an approach in which virus-mediated expression systems were used for target functionality validation and HTS. The flexible modular design of our expression system facilitates the creation of both adenovirus and baculovirus systems, thus effectively reducing time between target validation and HTS. The incorporation of epitope affinity tags greatly facilitates purification. A recombinant adenovirus was used to overexpress the target gene in vivo, and a baculovirus expression system attained high levels of recombinant protein expression using cultured insect cells. Validation of a potential target functionality in vivo was achieved using intrabrain administration of target-expressing recombinant adenovirus, which resulted in increased levels of a relevant biomarker. The target protein generated in the baculovirus system was used for HTS. Hence, viral expression systems allowed for rapid transition from target functionality validation to HTS.
MATERIALS AND METHODS

Recombinant adenovirus construction
The 6.9-kb transfer vector pQBI-ADBM5 in which the transcriptional cassette is flanked by a recombination sequence (Quantum Biotechnologies, Montreal, Quebec, Canada) was modified by oligonucleotide insertion to replace the sequences in between the 2 Eco RI sites in pQBI-ADBM5 with sites encoding for Sfi I and Pac I for subsequent linearization prior to homologous recombination. The target protease was subcloned in-frame of a C-terminal Zs green fluorescent protein (GFP)-HA-6HIS fluorescent epitope affinity tag downstream from the CMV promoter (1.5-kb insert), whereas the gene encoding the target substrate (2.2 kb) was subcloned in-frame of a C-terminal GFP-FLAG-6HIS epitope affinity tag. The ZsGFP sequences were obtained from Clontech (Clontech, Palo Alto, CA). Cloning steps were performed as previously described. 4 Recombinant adenoviruses were prepared by standard procedures. The target and substrate-expressing transfer vectors described above were digested with Sfi I and cotransfected with QBIviral DNA into QBI-293A cells using the calcium phosphate transfection method. Cells were overlaid with 5% SeaPlaque agarose (FMC BioProducts) in culture media in accordance with the manufacturer's recommendation (Quantum). Recombinant viral plaques were identified by fluorescence, following a 10-day incubational period, and isolated. After 2 rounds of plaque purification, viral stocks were amplified and used for subsequent studies.
Enzyme expression and purification
The target, which in this case was a membrane-bound aspartic protease, was made soluble by removing the C-terminal transmembrane domain and subcloned in-frame of a C-terminal HA-6HIS epitope affinity tag in the transplacement vector pFastBac1. The corresponding baculovirus was generated following BAC-TO-BAC Baculovirus Expression System specifications (Life Technologies, Rockville, MD). Sf9g/399 cells were grown into 10 6 cells/ml in 30 L of Sf900 II media and infected with recombinant baculovirus virus at a multiplicity of infection of 1 and harvested 96 h later. The culture medium was collected and concentrated with a Dynapure Hollow Fiber module with MWCO: 30,000 daltons (Daly Engineered Filtration, Naperville, IL), and the resulting concentrate was dialyzed against two 18-L changes of 50 mM NaH 2 PO 4 (pH 8.0) and 100 mM NaCl. The target protein was then purified using Ni-NTA resin as described in the manufacturer's protocol (Qiagen, Valencia, CA), and a yield of approximately 30 mg was obtained.
Protease reaction
To run the enzyme reaction, 15 µl of the recombinant target protease at 4 µg/ml was added to an LJL HE96 plate (Molecular De-vices, Sunnyvale, CA) followed by either 2 µl of compound in 30% DMSO (final compound concentration of 30 µM) or vehicle. Then, 10 µl of a substrate labeled with 5-[(2-aminoethyl) amino] naphthalene-1-sulfonic acid (EDANS) (AnaSpec, San Jose, CA) and 4-(4-dimethylaminophenyl) azo benzoic acid (DABCYL) (AnaSpec) was added to a final concentration of 10 µM. The samples were incubated at 37°C for 60 min and amidolytic activity measured using a PolarStar fluorescent plate reader at 355 nm excitation and 520 nm emission.
High-throughput screening (HTS) system and computer data processing
Allegro modules sequence: Data were processed in Activity Base according to manufacturer specifications (ID Business Solutions Ltd., Emeryville, CA).
RESULTS
In all experiments presented, a replication-deficient adenovirusmediated gene delivery system was used. Figure 1 schematizes the viral constructs used in the experimental strategy. The ability of recombinant adenovirus vectors to transduce cells both in vivo and in vitro, along with using GFP fluorescence to monitor expression, greatly simplifies their use. Likewise, the incorporation of additional epitope affinity tags for the identification and purification of expressed recombinant proteins generalizes the overall strategy to facilitate target validation of recently identified gene products. The cassette-based modular design of these viral vectors facilitates generation of different viral constructs, reducing time between target validation and HTS. The GFP fluorescence accelerated the identification and isolation of recombinant viral plaques because they could readily be identified using conventional fluorescent microscopy ( Fig. 2A) .
The ability of the target, which is in this case a protease, to cleave its relevant substrate was first validated using QBI-293A cells and SK-N-MC cells that were infected with the target-expressing adenovirus, a substrate coding adenovirus, or both. Cell fluorescence (indicating GFP expression) was detected using fluorescent microscopy (Fig. 2B ). Coexpression of the protease of interest, along with its substrate, resulted in elevated levels of cleavage products that were detected by Western blot analysis (Fig. 2C ). In addition, incorporation of the FLAG epitope tag in the substrate construct allowed for its purification, along with the relevant Cterminal cleavage product, by incubating infected cell lysates with Affi-FLAG resin and eluting with an excess of FLAG peptide. Binding to resin and efficient elution could easily be monitored by fluorescence microscopy (Fig. 2D ). Analysis of the eluted fraction by polyacrylamide gel electrophoresis and staining with Coomassie Brilliant Blue revealed the full-length substrate and a lower molecular weight cleavage product. The appropriate cleavage site of the product was confirmed by N-terminal sequence analysis of the purified product (data not shown).
In studies in vivo, recombinant adenoviruses expressing the protease, its substrate, or both (10 7 plaque-forming units of each, in 2.5 µl of sterile PBS) were infused directly into the cortex of mice. Following 48 h after adenoviral delivery, brains were removed, and GFP fluorescence, observed using a Nikon Eclipse E600 microscope (excitation = 420-490 nm and emission = 520 nm), was used to verify delivery. Brains were either fixed in 10% formalin neutral buffered solution (Sigma Diagnostics, St. Louis, MO) or homogenized in PBS containing 0.5% Triton X100 (Sigma-Aldrich). Fixed brains were cut in sections, and a three-dimensional pattern of target expression was analyzed using confocal laser scanning microscopy (Fig. 3A) . Western blot analysis of brain homogenates revealed a target protease-specific cleavage product only in those brains cotransduced with both substrate and protease (Fig. 3B) . The cleavage product detected in the samples prepared from the brains of cotransduced mice was identical to that detected previously from cotransduced cell cultures.
The modular design of expression vectors facilitated rapid generation of a baculovirus expression system for the target protein.
This system, coupled with 6HIS tag-based affinity purification, provided an economical way to produce sufficient amounts of target protein for our HTS studies. The HTS assay was developed using a quench-based fluorescence resonance energy transfer (FRET) system. Cleavage of the substrate resulted in a release from the quenched fluorescence state, and thus an increase in fluorescence intensity could be measured (Fig. 4) . The assay was linear with time for up to 90 min and linear with enzyme concentration (Fig. 5 ) and substrate concentration over the range chosen for the assay (Fig. 6 ).
The HTS assay was performed using an Allegro Ultra High Throughput system from Zymark. We found this assay relatively easy to run with a throughput of 350 96-well plates in a 12-h day. A typical Z′ for this assay was 0.55. 6 Data were calculated using Activity Base (Fig. 7 ). An active compound was considered to have 50% inhibition or greater. Using this criteria, the hit rate for 250,000 compounds screened was 0.76% with a 26% confirmation rate.
DISCUSSION
The postgenome era of drug discovery will rely heavily on targets identified through current genomics and bioinformatics efforts. Comparative work on complete human protease families should produce a more integrated picture of their biochemistry and physiology. 7 Genomic data will also lead to the identification of novel proteases involved in disease processes and their evaluation as drug targets. However, a conceptual bottleneck is the validation of target proteins derived through this process. Thus, a significant number of potential novel targets derived from bioinformatics require more efficient tools to investigate target biology and medical importance.
One approach to understanding the function of a novel sequence involves modulation of its expression. Adenovirusmediated gene delivery allows an efficient way to deliver genes of interest to cells in vivo and in vitro. One particular advantage of adenoviral vectors is their ability to transduce neurons, thus offer- FIG. 1. Overall experimental strategy. Target functionality validation in vivo and in vitro was achieved using target-and substrate-expressing adenoviruses. Substrate cleavage at a specific site resulted in elevated levels of a disease-relevant biomarker. Green Fluorescent Protein (GFP) fluorescence served as an effective way to monitor expression, and epitope affinity tags, indicated as HA, FLAG, or HIS, allowed for rapid purification of target protein for high-throughput screening (HTS) as well as the substrate cleavage products in cell-based models. The modular design of these viral vectors promotes subcloning for the generation of subsequent viral expression constructs, reducing time between target validation and HTS.
Virus-Based Expression Systems Facilitate Target Validation
ing an efficient way to generate cell and animal models of certain CNS-related diseases. The use of target gene-fluorescent GFP fusions represents a convenient approach to facilitate recombinant adenovirus production and monitor transduced gene delivery, expression, and cell localization. The application of GFP-expressing adenoviruses also allows for an attractive way to monitor gene ex-pression using fiber-optic-based systems. 8 Furthermore, it serves as a reliable strategy to control uniformity of gene transfer and expression if the objective is scaling up for HTS cell-based assay applications.
Previous studies demonstrated efficacy of the adenoviralmediated glial cell line-derived neurotrophic factor (GDNF) gene transfer in vivo using a progressive lesion model of Parkinson disease. 9 Rats received unilateral injections into their striatum, first of recombinant adenovirus, followed by 6-hydroxydopamine 6 days later. Mesencephalic nigral dopamine neurons of animals treated with the GDNF-expressing adenovirus were protected, whereas those of animals treated with the control adenovirus expressing beta-galactosidase were not. In another report, 10 adenovirus vectors encoding either the beta-galactosidase gene or the endothelial nitric oxide synthase gene (Ad-eNOS) were transfected into the nucleus tractus solitarii. In the AdeNOS-transduced rats, blood pressure and heart rate significantly changed relative to control animals. Recombinant adenovirus-based expressional systems permit the delivery of a wide range of genes that often result in the anticipated biological effects of the genes transduced. 5, 6, 11 Simplicity of construction and the potential to obtain a high titer viral stock make adenovirus a compelling option to characterize and validate novel target proteins. Adenovirus-based gene function validation services are also commercially available from several vendors, in-cluding Galapagos (Galapagos Genomics BV, Leiden, the Netherlands). In this report, recombinant adenoviruses allowed a rapid and efficient way to express genes of interest in the brain. Expression of the target protease resulted in the accumulation of a relevant biomarker, which was a cleavage product from its substrate. In this case, the substrate was expressed from a cotransduced second recombinant adenovirus. The accumulation of this biomarker confirmed the biological role of this target in vivo and represents a major advance toward the development of an animal model for in vivo drug evaluation. This approach may be applicable to a wide range of potential targets and could facilitate a process of target validation animal model development for drug discovery. The advantages of the approach presented are (1) the flexibility of target gene delivery both in vitro and in vivo, (2) an efficient delivery system for the target gene accompanied by high levels of protein expression, (3) incorporation of epitope affinity tags in the constructs that permit detection and purification of both target and substrate proteins, (4) the monitoring of expression levels using fluorescence, and (5) a rapid transition to baculovirus for large-scale protein production, accompanied by efficient isolation and purification of the affinity-tagged recombinant protein, for use in cell-free assays, biochemical characterization, and HTS applications. In theory, this system could provide the ability to perform measurements of target activity in vitro, in parallel with the target activity in virally transduced cultured cells, as well as in vivo. Therefore, it should enable both rapid evaluation of library compounds and analyses of structure-activity relationships of analogs synthetically derived through medicinal chemistry following the identification of active FIG. 7 . Control data generated from Activity Base calculations: Robotic-generated assay data from a representative control plate, calculated using Activity Base, are shown. Each control plate contains a titration of protease inhibitor standard, and the standard dose-response curve is shown on the righthand side of the screen shot. leads, as well as their biological activity in cell-based and animal models, thus accelerating the drug discovery process.
